USANA Health Sciences (USNA) Misses Q3 EPS by 5c; revises guidance

USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $0.59, $0.05 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $213 million versus the consensus estimate of $227.79 million.

GUIDANCE:

USANA Health Sciences sees FY2023 EPS of $2.80-$3.05, versus the consensus of $3.13. USANA Health Sciences sees FY2023 revenue of $900-920 million, versus the consensus of $930 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance